10-Q: Cell MedX Corp. Reports Q2 2024 Results, Faces Going Concern Challenges Amidst Debt Restructuring

Cell MedX Corp.'s Q2 2024 report reveals no revenue, a significant net loss, and a substantial working capital deficit, alongside a major debt-for-equity swap and management changes.

Summary

• Cell MedX Corp. reported its financial results for the quarter ended November 30, 2023, showing no revenue compared to $1,950 in the same period last year.
• The company's net loss for the quarter was $60,547, an improvement from the $142,813 loss in the prior year's quarter.
• Operating expenses decreased significantly to $42,562 from $132,573 year-over-year, primarily due to reduced general and administrative costs and research and development expenses.
• The company's working capital deficit increased to $2,525,492 from $2,385,480 at the end of the previous fiscal year.
• Cell MedX has accumulated a deficit of $10,290,277 since inception and faces substantial doubt about its ability to continue as a going concern.
• A significant debt settlement occurred post-quarter end, converting $1,622,693 of debt into 231,813,310 shares of common stock at $0.007 per share.
• This debt settlement resulted in a change of control of the company, with David Jeffs and Amir Vahabzadeh becoming major shareholders and joining the board of directors.
• The company's eBalance technology commercial activities remain suspended due to the loss of Health Canada licenses.

Sentiment

Score: 2

Explanation: The document reveals significant financial distress, lack of revenue, and a going concern issue, despite some cost-cutting measures and a debt restructuring. The overall outlook is highly negative.

Positives

• The net loss decreased compared to the same periods in the previous year, indicating some cost control.
• Operating expenses were significantly reduced, primarily due to lower general and administrative costs and research and development expenses.
• The debt settlement significantly reduced the company's liabilities and working capital deficit.
• The company has a new CEO and board members with relevant experience.

Negatives

• The company generated no revenue for the reported periods, indicating a complete halt in sales.
• The company has a substantial accumulated deficit of $10,290,277 since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's eBalance technology commercial activities are suspended due to the cancellation of Health Canada licenses.
• The company has a significant working capital deficit of $2,525,492.

Risks

• The company operates in a highly competitive market with well-established competitors.
• The company is subject to numerous governmental regulations, which can increase costs and delay product development.
• The company's intellectual property rights may not be adequately protected or enforced.
• The company's research and development efforts may not result in commercially successful products.
• The company may face significant safety concerns with its products, which could negatively impact sales.
• The company's ability to attract and maintain key personnel is critical to its success.
• The company has a limited operating history and has generated minimal revenues to date.
• The company needs to acquire additional financing, or its business will fail.
• The company's stock is a penny stock, which limits shareholders' ability to sell their stock.
• The company has not paid and does not anticipate paying cash dividends on its common stock.

Future Outlook

The company's future is uncertain, dependent on securing additional financing and achieving profitable operations. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.

Management Comments

• Management believes all adjustments necessary for a fair presentation of the results of operations and financial position have been included.
• Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.
• Management is planning to mitigate the Company's shortfall in funds through equity or debt financing.

Industry Context

The company operates in the competitive biotech and medical device industry, facing challenges from larger, well-established companies. The suspension of their eBalance technology commercial activities due to regulatory issues highlights the risks associated with this sector.

Comparison to Industry Standards

• Cell MedX's lack of revenue and significant losses are concerning when compared to established medical device companies like Bayer Corp., Becton Dickinson Corp., and Johnson & Johnson's LifeScan Inc., which have consistent revenue streams and profitability.
• The company's reliance on related-party loans and debt conversions is not typical of well-funded biotech companies, which often have access to venture capital or public markets.
• The suspension of commercial activities due to regulatory issues is a significant setback, as most successful medical device companies maintain compliance with regulatory standards.
• The debt-for-equity swap, while reducing liabilities, is a common strategy for distressed companies, but it also dilutes existing shareholders and indicates financial instability.

Management Changes

Corporate Governance

Related Party Transactions

• The company has significant transactions with related parties, including loans, advances, and consulting fees.
• A company controlled by the former COO and current director assigned a total of $682,590 owed to it in separate transactions; of this amount a total of $425,590 were transferred to the Company's related parties.
• The company's CEO assigned a total of $76,500 owed to him to Mr. Vahabzadeh a significant shareholder of the Company.
• Mr. Richard Jeffs reassigned notes payable to Mr. David Jeffs subsequent to the quarter end.
• Mr. Vahabzadeh acquired debt from one of the company's note holders.

Stakeholder Impact

• Shareholders have experienced significant dilution due to the debt-for-equity swap.
• Employees may face uncertainty due to the company's financial instability and management changes.
• Customers are impacted by the suspension of eBalance technology sales.
• Creditors have been impacted by the debt settlement and may face further uncertainty.
• Suppliers may be impacted by the company's financial instability.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to address the regulatory issues that led to the suspension of its eBalance technology commercial activities.
• The company needs to develop a new business plan and strategy under the new management team.

Key Dates

Keywords

Cell MedX, biotech, eBalance Technology, microcurrent, medical devices, debt settlement, going concern, financial results, Health Canada, regulatory approvals